1st Cardiology Unit, Hippokration Hospital, Athens University Medical School, Greece.
Curr Pharm Des. 2013;19(9):1569-80.
Stable angina represents the main symptom of established coronary artery disease. In addition atherosclerosis is the common pathological substrate of chronic stable angina as well as acute coronary syndromes. The aim of stable angina management is the symptomatic relief and the secondary prevention. Lifestyle modification and pharmacological therapy are the cornerstones of chronic coronary artery disease management irrespectively of possible surgical or percutaneous revascularization. Optimal medical therapy is a combination of antianginal/antiischemic drugs and disease modifying agents, including nitrates, beta-blockers, calcium channel blockers, antiplatelets, statins and angiotensin converting enzyme inhibitors. Novel classes of treatment with different mechanisms of action have been developed in the last years, including nicorandil, ivabradine, trimetazidine and ranolazine. These drugs, which are currently approved as second-line treatments, have dynamically entered the clinical practice and their long-term effects are still under investigation.
稳定型心绞痛是已确诊冠心病的主要症状。此外,动脉粥样硬化是慢性稳定型心绞痛和急性冠脉综合征的共同病理基础。稳定型心绞痛管理的目的是缓解症状和二级预防。生活方式的改变和药物治疗是慢性冠状动脉疾病管理的基石,无论是否可能进行手术或经皮血运重建。最佳的药物治疗是联合应用抗心绞痛/抗缺血药物和改善疾病的药物,包括硝酸酯类、β受体阻滞剂、钙通道阻滞剂、抗血小板药物、他汀类药物和血管紧张素转换酶抑制剂。近年来,已经开发出了具有不同作用机制的新型治疗药物,包括尼克地尔、伊伐布雷定、曲美他嗪和雷诺嗪。这些药物目前被批准为二线治疗药物,已在临床上得到广泛应用,但其长期疗效仍在研究中。